The Food and Drug Administration approved Eli Lilly’s Kisunla on Tuesday for mild or early cases of dementia caused by ...
The agency determined that the potential of slowing the devastating disease in patients with mild cognitive impairment ...
The Food and Drug Administration on Tuesday approved Eli Lilly’s Alzheimer’s drug, the company announced, clearing the way ...
Alzheimer’s drug that can slow the disease by several months. FDA approves a second Alzheimer’s drug that can slow the ...
The FDA approved the experimental Alzheimer's drug donanemab. The drug will be sold under the brand name Kisunla.
The U.S. Food and Drug Administration on Tuesday approved another drug that slows cognitive and functional decline in people ...
"Every step forward brings us a little bit closer to a world without Alzheimer's," said Beth Sulkowski, Alzheimer's ...
The FDA approved Kisunla, known chemically as donanemab ... aren’t yet setup to prescribe the new plaque-targeting Alzheimer's drugs. First, doctors need to confirm that patients with dementia ...
The Food and Drug Administration announced Tuesday the approval of a new Alzheimer ’s drug from Eli Lilly, which has demonstrated moderately slow cognitive and memory decline in patients with the ...
The Food and Drug Administration approved a new Alzheimer's treatment ... anti-amyloid treatments greenlighted by the FDA to date for Alzheimer's already carry a boxed warning about "amyloid ...